XO

XOMA Corp

  • CIK: 0000791908
  • EIN: 52-2154066
  • Business address: 2200 POWELL STREET, SUITE 310, EMERYVILLE, California, 94608

Information

  • Mailing address
    2200 POWELL STREET, SUITE 310, EMERYVILLE, CA, 94608
  • Phone
    510-204-7239
  • State location
    California
  • State of incorporation
    N/A
  • Fiscal year end
    December 31
  • SIC
    2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
  • Filings
    N/A

About XOMA Corp

XOMA Corp (CIK: 0000791908) is an American company incorporated in the state of California. Head office is located at 2200 POWELL STREET, SUITE 310, EMERYVILLE, California, 94608. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. XOMA Corp is a public company and trade via Over-The-Counter (OTC).

Old names:

  • XOMA LTD /DE/ from 2001-13-Dec to 2012-17-Jan
  • XOMA CORP /DE/ from 1996-23-Apr to 1998-19-Mar

Ownership

Owner Filings Transaction Date Type of Owner
Hughes Owen 0001575933 Jan-03-2023 director, officer: Interim CEO
Sitko Bradley 0001959809 Jan-03-2023 officer: Chief Investment Officer
Franklin Heather L 0001436658 Aug-06-2021 director
Hernday Natasha 0001780547 Jun-30-2020 director
BVF I GP LLC 0001803805 Mar-13-2020 10 percent owner
BVF II GP LLC 0001803806 Mar-13-2020 10 percent owner
BVF GP HOLDINGS LLC 0001803809 Mar-13-2020 10 percent owner
Kosacz Barbara 0001763316 Jan-01-2019 director
DATTA DEEPSHIKHA 0001731721 Feb-14-2018 officer: Chief Business Officer
PERRY MATTHEW D 0001454337 Feb-16-2017 director, other: See Explanation of Responses
BIOTECHNOLOGY VALUE FUND L P 0000918923 Feb-10-2017 other: See Explanation of Responses
BVF PARTNERS L P/IL 0001055947 Feb-10-2017 10 percent owner
BVF INC/IL 0001056807 Feb-10-2017 10 percent owner
BIOTECHNOLOGY VALUE FUND II LP 0001102444 Feb-10-2017 other: See Explanation of Responses
LAMPERT MARK N 0001233840 Feb-10-2017 10 percent owner
Biotechnology Value Trading Fund OS LP 0001660683 Feb-10-2017 other: See Explanation of Responses
BVF Partners OS Ltd. 0001660684 Feb-10-2017 other: See Explanation of Responses
BURNS THOMAS M. 0001638479 Apr-03-2015 officer: Chief Financial Officer
HUTT PETER BARTON 0001171527 May-22-2014 director
LIMBER JOSEPH M 0001216023 Mar-10-2014 director
Neal James R 0001600865 Feb-27-2014 officer: VP Business Development
Klein Thomas 0001572521 Dec-31-2013 officer: Chief Commercial Officer
WYSZOMIERSKI JACK L 0001023225 Nov-13-2013 director
VAN NESS W DENMAN 0001221676 Nov-13-2013 director
BOWES WILLIAM K JR 0001225476 Nov-13-2013 director
KURLAND FRED 0001267273 Nov-13-2013 officer: CFO & VP Finance
Walbert Timothy P 0001349376 Nov-13-2013 director
RUBIN PAUL D 0001210905 Aug-14-2013 officer: Sr. VP Clinical Dev. & CMO
SCANNON PATRICK J MD PHD 0001222790 Aug-14-2013 director, officer: Exec. VP & CSO
Varian John 0001416176 Jul-15-2013 director, officer: Director and CEO
Baker Bros. Advisors (GP) LLC 0001580575 Jul-01-2013 director, 10 percent owner
Baker Brothers Life Sciences LP 0001363364 Jul-19-2012 director
14159, L.P. 0001551138 Jul-19-2012 director
667, L.P. 0001551139 Jul-19-2012 director
Neu Kelvin 0001554699 Jul-19-2012 director
BAKER BROS ADVISORS LLC 0001263508 Apr-12-2012 10 percent owner
BAKER JULIAN 0001087939 Mar-06-2012 10 percent owner
BAKER FELIX 0001087940 Mar-06-2012 10 percent owner
Baker Biotech Capital (GP), LLC 0001244389 Mar-06-2012 10 percent owner
Baker Brothers Life Sciences Capital (GP), LLC 0001307729 Mar-06-2012 10 percent owner
14159 capital (GP), LLC 0001317493 Mar-06-2012 10 percent owner
ZENNER PATRICK J 0001139036 Jul-22-2010 director
ENGLE STEVEN B 0001234368 Aug-03-2007 director, officer: CEO and President
FISHER CHARLES J JR 0001408469 Jul-25-2007 director
BOYLE J DAVID II 0001331152 Jun-30-2005 officer: VP, Finance, and CFO
DELLIO CLARENCE L 0001221680 Dec-31-2003 officer: Sr VP, Operations and COO
MARGOLIN CHRISTOPHER J 0001222791 Dec-31-2003 officer: VP, General Counsel & Sec'y
CASTELLO JOHN L 0001222786 Nov-04-2003 director, officer: Chairman, CEO & President
DAVIS PETER B 0001222789 Jun-30-2003 officer: VP, Finance & CFO
ANDRESS JAMES G 0001014093 May-22-2003 director
MENDELL STEVEN C 0001222009 May-22-2003 director
KORNBERG ARTHUR MD 0001222045 May-22-2003 director

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by XOMA Corp

Filings Format Description Filed/Effective File/Film Number
SC TO-T Document

Third party tender offer statement

Acc-no: 0001193125-25-182241 ( Act) Size: KB		 Aug-18-2025

8-K Document

Current report filing

Acc-no: 0001193125-25-181840 (34 Act) Size: KB		 Aug-15-2025

001-39801

251224496
SC TO-T Document

Third party tender offer statement

Acc-no: 0001193125-25-181352 ( Act) Size: KB		 Aug-15-2025

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0001214659-25-012264 ( Act) Size: 0 KB		 Aug-14-2025

3 Document

Initial statement of beneficial ownership of securities

Acc-no: 0001214659-25-012263 ( Act) Size: 0 KB		 Aug-14-2025

8-K Document

Current report filing

Acc-no: 0001193125-25-179446 (34 Act) Size: KB		 Aug-13-2025

001-39801

251209014
10-Q Document

Quarterly report pursuant to sections 13 or 15(d)

Acc-no: 0001558370-25-011305 (34 Act) Size: KB		 Aug-13-2025

001-39801

251209012
SC TO-T/A Document

Amendment to Third party tender offer statement

Acc-no: 0001193125-25-177546 ( Act) Size: KB		 Aug-11-2025

SCHEDULE 13G/A Document Acc-no: 0000315066-25-002157 (34 Act) Size: KB Aug-06-2025

005-38028

251188537
SC TO-C Document

Written communication relating to an issuer or third party tender offer

Acc-no: 0001193125-25-172184 ( Act) Size: KB		 Aug-04-2025

SC TO-C Document

Written communication relating to an issuer or third party tender offer

Acc-no: 0001193125-25-172163 ( Act) Size: KB		 Aug-04-2025

SCHEDULE 13G Document Acc-no: 0000932471-25-001083 (34 Act) Size: KB Jul-29-2025

005-38028

251160792
SC TO-T/A Document

Amendment to Third party tender offer statement

Acc-no: 0001193125-25-163557 ( Act) Size: KB		 Jul-24-2025

SC TO-T Document

Third party tender offer statement

Acc-no: 0001193125-25-157812 ( Act) Size: KB		 Jul-11-2025

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0001214659-25-009988 ( Act) Size: 0 KB		 Jul-02-2025

SC TO-C Document

Written communication relating to an issuer or third party tender offer

Acc-no: 0001193125-25-149747 ( Act) Size: KB		 Jun-27-2025

SCHEDULE 13G/A Document Acc-no: 0000895421-25-000411 (34 Act) Size: KB Jun-06-2025

005-38028

251030814
8-K Document

Current report filing

Acc-no: 0001193125-25-132200 (34 Act) Size: KB		 May-30-2025

001-39801

251011438
4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0001214659-25-008324 ( Act) Size: 0 KB		 May-23-2025

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0001214659-25-008323 ( Act) Size: 0 KB		 May-23-2025

Recent 20 filings. View all XOMA Corp filings

Reviews

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Frequently Asked Questions

Tags:

  • XOMA Corp overview
  • XOMA Corp job
  • XOMA Corp stock
  • XOMA Corp ownership
  • XOMA Corp CEO
  • XOMA Corp documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

atai Life Sciences Luxembourg S.A.
Update: Sep 23, 2025
Hyperliquid Strategies Inc
Update: Sep 05, 2025
Polaryx Therapeutics, Inc.
Update: Sep 05, 2025
Nasus Pharma Ltd
Update: Jul 10, 2025
Promicell, Inc.
Update: May 30, 2025
Maius Pharmaceutical Group Co., Ltd.
Update: Mar 01, 2025

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 3150 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 1273 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 3797 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 2510 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 2741 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 2366 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 4046 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 3410 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 2550 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by